Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sierra Oncology Inc (NQ: SRRA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 54.96 (50)
Ask (Size) 55.00 (2)
Prev. Close 54.99
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 24,419,349
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
From Sierra Oncology
Via Business Wire

Performance

More News

Read More
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Via InvestorPlace
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
Recap: Sierra Oncology Q1 Earnings
Via Benzinga
Analyst Ratings for Sierra Oncology
Via Benzinga
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Reports First Quarter 2022 Results
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
From Kuznicki Law PLLC
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
From Kahn Swick & Foti, LLC
Via Business Wire
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Via Benzinga
Analyzing Sierra Oncology Inc's Short Interest
Via Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Creatd (CRTD) Stock Up Today?
Via InvestorPlace
Dear KLDO Stock Fans, Mark Your Calendars for April 28
Via InvestorPlace
Why Is Sierra Oncology (SRRA) Stock Up Today?
Via InvestorPlace
Sierra Oncology Stock Is Soaring: Here's Why
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Via Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
Via Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Via Benzinga
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.